

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC

CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock code: 1093)

**APPOINTMENT OF VICE-CHAIRMAN
AND
CHANGE OF ROTATING CHIEF EXECUTIVE OFFICER**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”) together with its subsidiaries, collectively the “**Group**”) hereby announces that with effect from 25 May 2018, (i) Mr. PAN Weidong (“**Mr. PAN**”), an executive director of the Company, ceased as Rotating Chief Executive Officer of the Company and remains as executive director and Vice-Chairman of the Company; and (ii) Mr. WANG Zhenguo (“**Mr. WANG**”), an executive director of the Company, has been appointed as the Vice-Chairman and Rotating Chief Executive Officer of the Company.

The biographical details of Mr. WANG are set out below:

Mr. WANG, aged 48, was appointed as an executive director of the Company in 2012. Mr. Wang is also a director of certain subsidiaries of the Group. Mr. Wang holds a bachelor’s degree in chemistry from Nankai University and has extensive technical and management experience in the pharmaceutical industry.

Mr. WANG does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”). Mr. WANG has entered into a service contract as an executive Director for a term of 3 years commencing from 1 April 2018. He is also subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the articles of association of the Company. His director’s fee is to be determined by the Board and to be authorised by the shareholders of the Company at the annual general meeting with reference to his performance and responsibilities, performance of the Group and prevailing market practices. Mr. WANG received

a director's fee of HK\$60,000 and other remuneration of HK\$4,773,000 for the year ended 31 December 2017. Mr. WANG does not receive any remuneration for acting as the vice-Chairman and Rotating Chief Executive Officer.

Save as disclosed above, Mr. WANG (i) has not held any other positions with any members of the Group; (ii) is not related to any director, senior management, substantial shareholders of the Company or controlling shareholders of the Company or other members of the Group; (iii) is not interested in the shares of the Company within the meaning of Part XV of the SFO; and (iv) has not held any other directorships in any other listed public companies in the last three years. Save as disclosed above, Mr. WANG has confirmed that there are no other matters that need to be brought to the attention of the shareholders of the Company in connection with the aforesaid appointment and there are no information that should be disclosed pursuant to rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board would like to take this opportunity to give appreciation to Mr. Pan for his contribution during his tenure as the Rotating Chief Executive Director and welcome Mr. WANG to the new positions.

By order of the board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 25 May 2018

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Mr. WANG Jinxu, Mr. LU Hua, Mr. LI Chunlei and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.